請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78238完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳俊任(Chun-Jen Chen) | |
| dc.contributor.author | Yu-Cheng Lin | en |
| dc.contributor.author | 林宥成 | zh_TW |
| dc.date.accessioned | 2021-07-11T14:47:17Z | - |
| dc.date.available | 2025-08-01 | |
| dc.date.copyright | 2020-08-24 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2020-08-17 | |
| dc.identifier.citation | 參考文獻 [1] C. L. Wang, C. Y. Lu, Y. C. Hsueh, W. H. Liu, and C. J. Chen, 'Activation of antitumor immune responses by Ganoderma formosanum polysaccharides in tumor-bearing mice,' (in eng), Appl Microbiol Biotechnol, vol. 98, no. 22, pp. 9389-98, Nov 2014. [2] P. M. Kirk and T. V. Andrianova, Dictionary of the fungi. Oxon: Cabi, 2008. [3] S. Li, Compendium of materia medica Book 2 Book 2. 2003. [4] M. K. Abdulridha, A. H. Al-Marzoqi, G. R. L. Al-Awsi, S. M. H. Mubarak, M. Heidarifard, and A. Ghasemian, 'Anticancer Effects of Herbal Medicine Compounds and Novel Formulations: a Literature Review,' (in eng), J Gastrointest Cancer, Mar 5 2020. [5] J. Wang, B. Cao, H. Zhao, and J. Feng, 'Emerging Roles of Ganoderma Lucidum in Anti-Aging,' Aging Dis, vol. 8, no. 6, pp. 691-707, Dec 2017. [6] N. H. N. Ubaidillah, N. Abdullah, and V. Sabaratnam, 'Isolation of the intracellular and extracellular polysaccharides of Ganoderma neojaponicum (Imazeki) and characterization of their immunomodulatory properties,' Electronic Journal of Biotechnology, vol. 18, no. 3, pp. 188-195, 2015. [7] Y. Yang et al., 'Advances in research on the active constituents and physiological effects of Ganoderma lucidum,' Biomedical Dermatology, vol. 3, no. 1, 2019. [8] C. Wang et al., 'Antitumor and Immunomodulatory Activities of Ganoderma lucidum Polysaccharides in Glioma-Bearing Rats,' Integrative Cancer Therapies, vol. 17, no. 3, pp. 674-683, 2018/09/01 2018. [9] K. Zhang et al., 'Anti-inflammatory properties of GLPss58, a sulfated polysaccharide from Ganoderma lucidum,' (in eng), Int J Biol Macromol, vol. 107, no. Pt A, pp. 486-493, Feb 2018. [10] Y. Cao, X. Xu, S. Liu, L. Huang, and J. Gu, 'Ganoderma: A Cancer Immunotherapy Review,' (in English), Frontiers in Pharmacology, Mini Review vol. 9, no. 1217, 2018-October-25 2018. [11] Y. H. Lee et al., 'Ethanol Extract of Ganoderma lucidum Augments Cellular Anti-oxidant Defense through Activation of Nrf2/HO-1,' J Pharmacopuncture, vol. 19, no. 1, pp. 59-69, Mar 2016. [12] C. Xiao, Q. Wu, J. Zhang, Y. Xie, W. Cai, and J. Tan, 'Antidiabetic activity of Ganoderma lucidum polysaccharides F31 down-regulated hepatic glucose regulatory enzymes in diabetic mice,' (in eng), J Ethnopharmacol, vol. 196, pp. 47-57, Jan 20 2017. [13] D.-J. Chung, M.-Y. Yang, Y.-R. Li, W.-J. Chen, C.-Y. Hung, and C.-J. Wang, 'Ganoderma lucidum repress injury of ethanol-induced steatohepatitis via anti-inflammation, anti-oxidation and reducing hepatic lipid in C57BL/6J mice,' Journal of Functional Foods, vol. 33, pp. 314-322, 2017. [14] D. Sohretoglu and S. Huang, 'Ganoderma lucidum Polysaccharides as An Anti-cancer Agent,' (in eng), Anticancer Agents Med Chem, vol. 18, no. 5, pp. 667-674, 2018. [15] L. Ye, S. Liu, F. Xie, L. Zhao, and X. Wu, 'Enhanced production of polysaccharides and triterpenoids in Ganoderma lucidum fruit bodies on induction with signal transduction during the fruiting stage,' PLoS One, vol. 13, no. 4, p. e0196287, 2018. [16] Z. Xu, X. Chen, Z. Zhong, L. Chen, and Y. Wang, 'Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities,' (in eng), Am J Chin Med, vol. 39, no. 1, pp. 15-27, 2011. [17] C. L. Wang et al., 'Extracellular polysaccharides produced by Ganoderma formosanum stimulate macrophage activation via multiple pattern-recognition receptors,' (in eng), BMC Complement Altern Med, vol. 12, p. 119, Aug 10 2012. [18] C. L. Wang et al., 'Polysaccharides purified from the submerged culture of Ganoderma formosanum stimulate macrophage activation and protect mice against Listeria monocytogenes infection,' (in eng), Biotechnol Lett, vol. 33, no. 11, pp. 2271-8, Nov 2011. [19] C.-C. Pi, H.-Y. Wang, C.-Y. Lu, F. L. Lu, and C.-J. Chen, 'Ganoderma formosanum polysaccharides attenuate Th2 inflammation and airway hyperresponsiveness in a murine model of allergic asthma,' SpringerPlus, vol. 3, no. 1, p. 297, 2014/06/12 2014. [20] S. Zhang, X. Yang, L. Wang, and C. Zhang, 'Interplay between inflammatory tumor microenvironment and cancer stem cells,' Oncol Lett, vol. 16, no. 1, pp. 679-686, Jul 2018. [21] D. C. Hinshaw and L. A. Shevde, 'The Tumor Microenvironment Innately Modulates Cancer Progression,' (in eng), Cancer Res, vol. 79, no. 18, pp. 4557-4566, Sep 15 2019. [22] N. S. Nicholas, B. Apollonio, and A. G. Ramsay, 'Tumor microenvironment (TME)-driven immune suppression in B cell malignancy,' Biochim Biophys Acta, vol. 1863, no. 3, pp. 471-482, Mar 2016. [23] E. Reeves and E. James, 'Antigen processing and immune regulation in the response to tumours,' (in eng), Immunology, vol. 150, no. 1, pp. 16-24, Jan 2017. [24] S. Mariathasan et al., 'TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells,' Nature, vol. 554, no. 7693, pp. 544-548, 2018/02/01 2018. [25] D. Fukumura, J. Kloepper, Z. Amoozgar, D. G. Duda, and R. K. Jain, 'Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges,' Nature Reviews Clinical Oncology, vol. 15, no. 5, pp. 325-340, 2018/05/01 2018. [26] T. Sato, M. Terai, Y. Tamura, V. Alexeev, M. J. Mastrangelo, and S. R. Selvan, 'Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy,' (in eng), Immunol Res, vol. 51, no. 2-3, pp. 170-82, Dec 2011. [27] G. W. Tormoen, M. R. Crittenden, and M. J. Gough, 'Role of the immunosuppressive microenvironment in immunotherapy,' Adv Radiat Oncol, vol. 3, no. 4, pp. 520-526, Oct-Dec 2018. [28] V. Kumar, S. Patel, E. Tcyganov, and D. I. Gabrilovich, 'The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment,' Trends Immunol, vol. 37, no. 3, pp. 208-220, Mar 2016. [29] Y. Liu et al., 'Targeting myeloid-derived suppressor cells for cancer immunotherapy,' (in eng), Cancer Immunol Immunother, vol. 67, no. 8, pp. 1181-1195, Aug 2018. [30] I. Mitroulis, L. Kalafati, G. Hajishengallis, and T. Chavakis, 'Myelopoiesis in the Context of Innate Immunity,' J Innate Immun, vol. 10, no. 5-6, pp. 365-372, 2018. [31] D. R. Barreda, P. C. Hanington, and M. Belosevic, 'Regulation of myeloid development and function by colony stimulating factors,' (in eng), Dev Comp Immunol, vol. 28, no. 5, pp. 509-54, May 3 2004. [32] C. R. Lee, W. Lee, S. K. Cho, and S. G. Park, 'Characterization of Multiple Cytokine Combinations and TGF-beta on Differentiation and Functions of Myeloid-Derived Suppressor Cells,' Int J Mol Sci, vol. 19, no. 3, Mar 15 2018. [33] S. Ostrand-Rosenberg and C. Fenselau, 'Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment,' J Immunol, vol. 200, no. 2, pp. 422-431, Jan 15 2018. [34] C. Groth et al., 'Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression,' Br J Cancer, vol. 120, no. 1, pp. 16-25, Jan 2019. [35] K. Hart, K. Byrne, M. Molloy, E. Usherwood, and B. Berwin, 'IL-10 Immunomodulation of Myeloid Cells Regulates a Murine Model of Ovarian Cancer,' (in English), Frontiers in Immunology, Original Research vol. 2, no. 29, 2011-July-21 2011. [36] X. Shao et al., 'Distinct alterations of CD68(+)CD163(+) M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment,' (in eng), J Transl Med, vol. 16, no. 1, p. 48, Mar 2 2018. [37] E. M. Hanson, V. K. Clements, P. Sinha, D. Ilkovitch, and S. Ostrand-Rosenberg, 'Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells,' (in eng), J Immunol, vol. 183, no. 2, pp. 937-44, Jul 15 2009. [38] P. Jayaraman et al., 'Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release,' (in eng), J Immunol, vol. 188, no. 11, pp. 5365-76, Jun 1 2012. [39] N. Köstlin-Gille et al., 'HIF-1α-Deficiency in Myeloid Cells Leads to a Disturbed Accumulation of Myeloid Derived Suppressor Cells (MDSC) During Pregnancy and to an Increased Abortion Rate in Mice,' (in English), Frontiers in Immunology, Original Research vol. 10, no. 161, 2019-February-05 2019. [40] Y. Wang, A. Jia, Y. Bi, Y. Wang, and G. Liu, 'Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer,' Cells, vol. 9, no. 4, Apr 18 2020. [41] J. Li et al., 'CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer,' (in eng), Oncoimmunology, vol. 6, no. 6, p. e1320011, 2017. [42] R. Weber et al., 'Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors,' (in eng), Front Immunol, vol. 9, p. 1310, 2018. [43] D. I. Gabrilovich, S. Ostrand-Rosenberg, and V. Bronte, 'Coordinated regulation of myeloid cells by tumours,' (in eng), Nat Rev Immunol, vol. 12, no. 4, pp. 253-68, Mar 22 2012. [44] M. Jiang et al., 'Interleukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer,' Front Immunol, vol. 8, p. 1840, 2017. [45] D. E. Johnson, R. A. O'Keefe, and J. R. Grandis, 'Targeting the IL-6/JAK/STAT3 signalling axis in cancer,' (in eng), Nat Rev Clin Oncol, vol. 15, no. 4, pp. 234-248, Apr 2018. [46] A. B. Roos and M. Nord, 'The emerging role of C/EBPs in glucocorticoid signaling: lessons from the lung,' J Endocrinol, vol. 212, no. 3, pp. 291-305, Mar 2012. [47] T. J. Shackleford et al., 'Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells,' (in eng), Breast Cancer Res, vol. 13, no. 3, p. R65, Jun 20 2011. [48] I. Marigo et al., 'Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor,' Immunity, vol. 32, no. 6, pp. 790-802, Jun 25 2010. [49] E. A. Conaway, D. C. de Oliveira, C. M. McInnis, S. B. Snapper, and B. H. Horwitz, 'Inhibition of Inflammatory Gene Transcription by IL-10 Is Associated with Rapid Suppression of Lipopolysaccharide-Induced Enhancer Activation,' J Immunol, vol. 198, no. 7, pp. 2906-2915, Apr 1 2017. [50] D. W. Beury, K. H. Parker, M. Nyandjo, P. Sinha, K. A. Carter, and S. Ostrand-Rosenberg, 'Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors,' (in eng), J Leukoc Biol, vol. 96, no. 6, pp. 1109-18, Dec 2014. [51] B. Huang et al., 'Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host,' (in eng), Cancer Res, vol. 66, no. 2, pp. 1123-31, Jan 15 2006. [52] B. Bierie and H. L. Moses, 'Transforming growth factor beta (TGF-beta) and inflammation in cancer,' (in eng), Cytokine Growth Factor Rev, vol. 21, no. 1, pp. 49-59, Feb 2010. [53] G. Srikrishna, 'S100A8 and S100A9: new insights into their roles in malignancy,' J Innate Immun, vol. 4, no. 1, pp. 31-40, 2012. [54] J. Yang, J. Anholts, U. Kolbe, J. A. Stegehuis-Kamp, F. H. J. Claas, and M. Eikmans, 'Calcium-Binding Proteins S100A8 and S100A9: Investigation of Their Immune Regulatory Effect in Myeloid Cells,' (in eng), Int J Mol Sci, vol. 19, no. 7, Jun 21 2018. [55] B. Carow and M. E. Rottenberg, 'SOCS3, a Major Regulator of Infection and Inflammation,' (in eng), Front Immunol, vol. 5, p. 58, 2014. [56] H. Yu et al., 'SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells,' (in eng), Cancer Immunol Res, vol. 3, no. 7, pp. 727-40, Jul 2015. [57] J. Decock, S. Thirkettle, L. Wagstaff, and D. R. Edwards, 'Matrix metalloproteinases: protective roles in cancer,' (in eng), J Cell Mol Med, vol. 15, no. 6, pp. 1254-65, Jun 2011. [58] M. J. Gorrin-Rivas et al., 'Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis,' (in eng), Clin Cancer Res, vol. 6, no. 5, pp. 1647-54, May 2000. [59] N. Merchant et al., 'Matrix metalloproteinases: their functional role in lung cancer,' Carcinogenesis, vol. 38, no. 8, pp. 766-780, 2017. [60] J. Li et al., 'Myeloid-derived suppressor cells accumulate among myeloid cells contributing to tumor growth in matrix metalloproteinase 12 knockout mice,' (in eng), Cell Immunol, vol. 327, pp. 1-12, May 2018. [61] F. Vannini, K. Kashfi, and N. Nath, 'The dual role of iNOS in cancer,' (in eng), Redox Biol, vol. 6, pp. 334-343, Dec 2015. [62] D. I. Gabrilovich and S. Nagaraj, 'Myeloid-derived suppressor cells as regulators of the immune system,' (in eng), Nat Rev Immunol, vol. 9, no. 3, pp. 162-74, Mar 2009. [63] M. Liu et al., 'Targeting the IDO1 pathway in cancer: from bench to bedside,' J Hematol Oncol, vol. 11, no. 1, p. 100, Aug 2 2018. [64] Z. Guo et al., 'COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells,' (in eng), Medicine (Baltimore), vol. 94, no. 44, p. e1806, Nov 2015. [65] M. Nakanishi and D. W. Rosenberg, 'Multifaceted roles of PGE2 in inflammation and cancer,' (in eng), Semin Immunopathol, vol. 35, no. 2, pp. 123-37, Mar 2013. [66] N. Obermajer and P. Kalinski, 'Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells,' (in eng), Oncoimmunology, vol. 1, no. 5, pp. 762-764, Aug 1 2012. [67] H. Garner and K. E. de Visser, 'Immune crosstalk in cancer progression and metastatic spread: a complex conversation,' Nat Rev Immunol, Feb 5 2020. [68] F. Veglia, M. Perego, and D. Gabrilovich, 'Myeloid-derived suppressor cells coming of age,' Nat Immunol, vol. 19, no. 2, pp. 108-119, Feb 2018. [69] D. Okwan-Duodu, G. E. Umpierrez, O. W. Brawley, and R. Diaz, 'Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages,' (in eng), Am J Cancer Res, vol. 3, no. 1, pp. 21-33, 2013. [70] J. Ye, 'Mechanisms of insulin resistance in obesity,' (in eng), Front Med, vol. 7, no. 1, pp. 14-24, Mar 2013. [71] N. A. Berger, 'Obesity and cancer pathogenesis,' (in eng), Ann N Y Acad Sci, vol. 1311, pp. 57-76, Apr 2014. [72] C. Hu, Y. Zhen, B. Pang, X. Lin, and H. Yi, 'Myeloid-Derived Suppressor Cells Are Regulated by Estradiol and Are a Predictive Marker for IVF Outcome,' (in eng), Front Endocrinol (Lausanne), vol. 10, p. 521, 2019. [73] K. R. Crook and P. Liu, 'Role of myeloid-derived suppressor cells in autoimmune disease,' (in eng), World J Immunol, vol. 4, no. 1, pp. 26-33, Mar 27 2014. [74] A. Ten Brinke et al., 'Monitoring T-Cell Responses in Translational Studies: Optimization of Dye-Based Proliferation Assay for Evaluation of Antigen-Specific Responses,' (in eng), Front Immunol, vol. 8, p. 1870, 2017. [75] S. Solito et al., 'Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo,' Curr Protoc Immunol, vol. 124, no. 1, p. e61, Feb 2019. [76] R. A. Dean, J. H. Cox, C. L. Bellac, A. Doucet, A. E. Starr, and C. M. Overall, 'Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx,' Blood, vol. 112, no. 8, pp. 3455-64, Oct 15 2008. [77] P. Ubanako, N. Xelwa, and M. Ntwasa, 'LPS induces inflammatory chemokines via TLR-4 signalling and enhances the Warburg Effect in THP-1 cells,' PLoS One, vol. 14, no. 9, p. e0222614, 2019. [78] V. Greifenberg, E. Ribechini, S. Rossner, and M. B. Lutz, 'Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development,' Eur J Immunol, vol. 39, no. 10, pp. 2865-76, Oct 2009. [79] Y. Yang et al., 'LPS expands MDSCs by inhibiting apoptosis through the regulation of the GATA2/let-7e axis,' (in eng), Immunol Cell Biol, vol. 97, no. 2, pp. 142-151, Feb 2019. [80] C. Yan, P. A. Ward, X. Wang, and H. Gao, 'Myeloid depletion of SOCS3 enhances LPS-induced acute lung injury through CCAAT/enhancer binding protein δ pathway,' (in eng), Faseb j, vol. 27, no. 8, pp. 2967-76, Aug 2013. [81] A. M. K. Law, F. Valdes-Mora, and D. Gallego-Ortega, 'Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer,' (in eng), Cells, vol. 9, no. 3, Feb 27 2020. [82] G. Mondanelli and C. Volpi, 'Differentiation of Myeloid-derived Suppressor Cells from Murine Bone Marrow and Their Co-culture with Splenic Dendritic Cells,' (in eng), Bio Protoc, vol. 7, no. 18, Sep 20 2017. [83] C. E. M. Aarts et al., 'Neutrophils as Suppressors of T Cell Proliferation: Does Age Matter?,' (in English), Frontiers in Immunology, Original Research vol. 10, no. 2144, 2019-September-11 2019. [84] A. M. Bruger et al., 'How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions,' Cancer Immunol Immunother, vol. 68, no. 4, pp. 631-644, Apr 2019. [85] J. Marino, J. Paster, and G. Benichou, 'Allorecognition by T Lymphocytes and Allograft Rejection,' (in eng), Front Immunol, vol. 7, p. 582, 2016. [86] K. Brown, A. K. Nowocin, L. Meader, L. A. Edwards, R. A. Smith, and W. Wong, 'Immunotoxin Against a Donor MHC Class II Molecule Induces Indefinite Survival of Murine Kidney Allografts,' (in eng), Am J Transplant, vol. 16, no. 4, pp. 1129-38, Apr 2016. [87] D. A. Boardman, J. Jacob, L. A. Smyth, G. Lombardi, and R. I. Lechler, 'What Is Direct Allorecognition?,' (in eng), Curr Transplant Rep, vol. 3, no. 4, pp. 275-283, 2016. [88] T. S. Lim, J. K. H. Goh, A. Mortellaro, C. T. Lim, G. J. Hämmerling, and P. Ricciardi-Castagnoli, 'CD80 and CD86 Differentially Regulate Mechanical Interactions of T-Cells with Antigen-Presenting Dendritic Cells and B-Cells,' PLOS ONE, vol. 7, no. 9, p. e45185, 2012. [89] Y. Zhan, A. M. Lew, and M. Chopin, 'The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game,' (in English), Frontiers in Immunology, Review vol. 10, no. 2679, 2019-November-15 2019. [90] J. Kurko et al., 'Suppression of proteoglycan-induced autoimmune arthritis by myeloid-derived suppressor cells generated in vitro from murine bone marrow,' PLoS One, vol. 9, no. 11, p. e111815, 2014. [91] V. Greifenberg, E. Ribechini, S. Rössner, and M. B. Lutz, 'Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development,' (in eng), Eur J Immunol, vol. 39, no. 10, pp. 2865-76, Oct 2009. [92] D. Y. Ma and E. A. Clark, 'The role of CD40 and CD154/CD40L in dendritic cells,' (in eng), Semin Immunol, vol. 21, no. 5, pp. 265-72, Oct 2009. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78238 | - |
| dc.description.abstract | 臺灣紫芝是在台灣所分離的天然靈芝物種。在先前我們已經證明，從臺灣紫芝的深層培養液中純化得到的多醣體。PS-F2在小鼠的腫瘤模式中，具有免疫調節和抗腫瘤特性。髓質衍生抑制型細胞 (myeloid-derived suppressor cells, MDSCs) 為在諸如癌症之病理條件下會擴張的異質髓質細胞群體。於腫瘤微環境裡，MDSCs可以發揮免疫抑制功能並促進腫瘤生長。 在本研究中，我們探討PS-F2是否可以透過直接調節MDSCs的免疫抑制能力來發揮抗腫瘤的功能。我們從C26大腸癌腫瘤小鼠的脾臟中分離出monocytic (M)-MDSCs和polymorphonuclear (PMN)-MDSCs。純化的M-MDSCs確實抑制了被anti-CD3e和anti-CD28抗體刺激的CD4+ T細胞的增生，而純化的PMN-MDSCs卻不影響T細胞的活化。然而，我們的結果顯示，PS-F2處理對M-MDSC的免疫抑制功能沒有顯著效果。另外，本研究也使用顆粒球-巨噬細胞集落刺激因子 (granulocyte-macrophage colony-stimulating factor, GM-CSF) 和白介素 (Interleukin, IL)-6培養了小鼠骨髓細胞，在體外產生骨髓衍生MDSCs (BM-MDSCs)。我們分析了PS-F2刺激對BM-MDSCs的免疫抑制、基因表達和成熟的影響。我們的結果顯示，BM-MDSCs能有效抑制T細胞增生，卻不受PS-F2的影響。PS-F2刺激並未有效改變BM-MDSCs中的基因表達。但是，給予PS-F2會促進成熟表面標記（例如CD11c，CD80和MHCII）的上調。與PS-F2相反，LPS刺激會導致BM-MDSCs免疫抑制活性的強化。總結而言，我們的結果說明了PS-F2可能不會透過直接調節MDSCs的免疫抑制功能，來發揮其抗腫瘤的作用。 | zh_TW |
| dc.description.abstract | Ganoderma formosanum is a native Ganoderma. species isolated in Taiwan, and we have previously shown that the PS-F2, a polysaccharide fraction purified from the submerged culture broth of G. formosanum, has immunomodulatory and anti-tumor properties in mice. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that expand in pathological conditions such as cancer. In the tumor microenvironment, MDSCs exert immunosuppressive functions and promote tumor growth. In the present study, we investigated whether PS-F2 may exert the anti-tumor effect by directly modulating the immunosuppressive effect of MDSCs. We isolated monocytic (M)-MDSCs and polymorphonuclear (PMN)-MDSCs from the spleen of C26 colorectal tumor-bearing mice. Purified M-MDSCs dose-dependently suppressed the proliferation of CD4+ T cells stimulated with anti-CD3ε and anti-CD28 antibodies, while purified PMN-MDSCs did not affect T cell proliferation. Our results showed that PS-F2 treatment did not have significant impact on the immunosuppressive function of M-MDSCs. We also cultured mouse bone marrow cells in granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-6 to generate bone marrow-derived MDSCs (BM-MDSCs) in vitro. We analyzed the effect of PS-F2 stimulation on immunosuppression, gene expression, and maturation of BM-MDSCs. Our results showed that BM-MDSCs effectively suppressed T cell proliferation, which was not affected by PS-F2. PS-F2 stimulation did not strongly alter the gene expression profile in BM-MDSCs. However, PS-F2 treatment resulted in the upregulation of maturation surface markers such as CD11c, CD80, and MHCII. In contrast to PS-F2, LPS stimulation resulted in enhanced immunosuppression of BM-MDSCs. Overall, our results indicate that PS-F2 may not exert its anti-tumor effect via directly modulating the immunosuppressive function of the MDSCs. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T14:47:17Z (GMT). No. of bitstreams: 1 U0001-1308202012393900.pdf: 8510731 bytes, checksum: 5c3ec3394ba52216b3192e3dfe6b120c (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | 目錄 致謝 II 中文摘要 III Abstract IV 縮寫表 V 表目錄 V 圖目錄 XI 研究動機 XII Chapter 1 緒論 1 1.1 靈芝簡介 1 1.2 靈芝多醣體的免疫調節活性 1 1.3 腫瘤微環境 (Tumor microenvironment, TME) 2 1.4 Myeloid-derived Suppressor Cell (MDSC) 3 1.4.1 分化途徑 3 1.4.2 表現型態 3 1.4.3 免疫抑制功能 4 1.4.4 抗發炎與腫瘤生長相關基因 5 1.4.5 病理相關 7 Chapter 2 材料與方法 9 2.1 動物與細胞株 9 2.2 培養基製備 9 2.2.1 固態培養基 (PDA medium) 9 2.2.2 液態培養基 (PDB medium) 9 2.2.3 發酵槽培養基 (ME-YE medium) 9 2.3 臺灣紫芝培養與胞外多醣 (PS-F2) 之純化與回收 10 2.3.1 菌種培養 10 2.3.2 發酵槽培養 10 2.3.3 回收胞外多醣 (cEPS) 10 2.3.4 粗多醣純化 10 2.3.5 測定醣濃度 11 2.4 C26大腸癌腫瘤小鼠的脾臟分離之MDSC 11 2.4.1 C26腫瘤模式小鼠建立 11 2.4.2 脾臟細胞製備 11 2.4.3 Biotin positive selection增量脾臟分離之MDSC 11 2.4.4 流式細胞儀分選MDSC 12 2.5未試驗小鼠的骨髓衍生之MDSC 12 2.5.1 骨髓細胞製備 12 2.5.2 骨髓衍生MDSC之培養策略 12 2.5.3 Biotin positive selection分選骨髓衍生MDSC 13 2.6 流式細胞術 (Flow cytometry, FCM) 13 2.7 CD4+ T cell negative selection分離Naïve T細胞 14 2.8 評估PS-F2或LPS對於MDSC的T細胞抑制功能之影響 14 2.9 骨髓衍生MDSC之基因表現 15 2.9.1 萃取mRNA 15 2.9.2 合成cDNA 15 2.9.3 Real-time Quantitative PCR (RT-qPCR) 16 2.10 統計與繪圖軟體分析 16 Chapter 3 結果 17 3.1 PS-F2對腫瘤小鼠脾臟分離MDSC之抑制功能的影響 17 3.2 腫瘤誘導之MDSC於PS-F2刺激後髓質成熟細胞標記的表現 17 3.3 BM-MDSC之in vitro分化平台建立與小鼠品系的選擇 18 3.4 最適化BM-MDSC培養策略 18 3.5 PS-F2刺激對BM-MDSC的免疫抑制功能之評估 19 3.6 BM-MDSC於PS-F2刺激後成熟髓質細胞標誌的表現 20 3.7 PS-F2對於BM-MDSC免疫抑制與MDSC相關基因之影響 20 3.8 LPS刺激對BM-MDSC的免疫抑制功能之評估 22 3.9 BM-MDSC於LPS刺激後成熟髓質細胞標誌的表現 22 3.10 LPS對於BM-MDSC免疫抑制與抗發炎相關基因之影響 22 Chapter 4 討論 24 參考文獻 62 | |
| dc.language.iso | zh-TW | |
| dc.subject | LPS | zh_TW |
| dc.subject | 臺灣紫芝 | zh_TW |
| dc.subject | PS-F2 | zh_TW |
| dc.subject | T細胞增生 | zh_TW |
| dc.subject | MDSC | zh_TW |
| dc.subject | Lipopolysaccharide | en |
| dc.subject | Ganoderma formosanum | en |
| dc.subject | Myeloid-derived suppressor cell | en |
| dc.subject | T cell proliferation | en |
| dc.subject | PS-F2 | en |
| dc.title | 臺灣紫芝多醣體對於髓質衍生抑制型細胞之影響 | zh_TW |
| dc.title | The effect of Ganoderma formosanum polysaccharides on myeloid-derived suppressor cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 徐立中(Li-Chung Hsu),陳念榮(Nien-Jung Chen) | |
| dc.subject.keyword | 臺灣紫芝,PS-F2,T細胞增生,MDSC,LPS, | zh_TW |
| dc.subject.keyword | Ganoderma formosanum,Myeloid-derived suppressor cell,T cell proliferation,PS-F2,Lipopolysaccharide, | en |
| dc.relation.page | 69 | |
| dc.identifier.doi | 10.6342/NTU202003224 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2020-08-18 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| dc.date.embargo-lift | 2025-08-01 | - |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1308202012393900.pdf 未授權公開取用 | 8.31 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。